Literature DB >> 21263462

Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells.

Lawrence W Leung1, Man-Seong Park, Osvaldo Martinez, Charalampos Valmas, Carolina B López, Christopher F Basler.   

Abstract

Ebolaviruses naturally infect a wide variety of cells including macrophages and dendritic cells (DCs), and the resulting cytokine and interferon-α/β (IFN) responses of infected cells are thought to influence viral pathogenesis. The VP35 protein impairs RIG-I-like receptor-dependent signaling to inhibit IFN production, and this function has been suggested to promote the ineffective host immune response characteristic of ebolavirus infection. To assess the impact of VP35 on innate immunity in biologically relevant primary cells, we used a recombinant Newcastle disease virus encoding VP35 (NDV/VP35) to infect macrophages and conventional DCs, which primarily respond to RNA virus infection via RIG-I-like pathways. VP35 suppressed not only IFN but also tumor necrosis factor (TNF)-α secretion, which are normally produced from these cells upon NDV infection. Additionally, in cells susceptible to the activity of VP35, IRF7 activation is impaired. In contrast, NDV/VP35 infection of plasmacytoid DCs, which activate IRF7 and produce IFN through TLR-dependent signaling, leads to robust IFN production. When plasmacytoid DCs deficient for TLR signaling were infected, NDV/VP35 was able to inhibit IFN production. Consistent with this, VP35 was less able to inhibit TLR-dependent versus RIG-I-dependent signaling in vitro. These data demonstrate that ebolavirus VP35 suppresses both IFN and cytokine production in multiple primary human cell types. However, cells that utilize the TLR pathway can circumvent this inhibition, suggesting that the presence of multiple viral sensors enables the host to overcome viral immune evasion mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263462      PMCID: PMC4148147          DOI: 10.1038/icb.2010.169

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  56 in total

1.  Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro.

Authors:  M Gupta; S Mahanty; R Ahmed; P E Rollin
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

2.  Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily.

Authors:  Lisa E Hensley; Howard A Young; Peter B Jahrling; Thomas W Geisbert
Journal:  Immunol Lett       Date:  2002-03-01       Impact factor: 3.685

Review 3.  Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback.

Authors:  David E Levy; Isabelle Marié; Eric Smith; Arun Prakash
Journal:  J Interferon Cytokine Res       Date:  2002-01       Impact factor: 2.607

4.  Inflammatory responses in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; A J Georges; M-C Georges-Courbot; M Capron; I Bedjabaga; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

5.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

6.  Newcastle disease virus V protein is a determinant of host range restriction.

Authors:  Man-Seong Park; Adolfo García-Sastre; Jerome F Cros; Christopher F Basler; Peter Palese
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.

Authors:  Adam Vigil; Man-Seong Park; Osvaldo Martinez; Mark A Chua; Sa Xiao; Jerome F Cros; Luis Martínez-Sobrido; Savio L C Woo; Adolfo García-Sastre
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.

Authors:  Thomas W Geisbert; Lisa E Hensley; Tom Larsen; Howard A Young; Douglas S Reed; Joan B Geisbert; Dana P Scott; Elliott Kagan; Peter B Jahrling; Kelly J Davis
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  30 in total

Review 1.  Viral manipulation of cellular protein conjugation pathways: The SUMO lesson.

Authors:  Domenico Mattoscio; Chiara V Segré; Susanna Chiocca
Journal:  World J Virol       Date:  2013-05-12

Review 2.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

3.  The ebolavirus VP24 interferon antagonist: know your enemy.

Authors:  Adrianna P P Zhang; Dafna M Abelson; Zachary A Bornholdt; Tong Liu; Virgil L Woods; Erica Ollmann Saphire
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

Review 4.  Characterization of a putative filovirus vaccine: virus-like particles.

Authors:  Karen A O Martins; Travis K Warren; Sina Bavari
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

5.  Inclusion bodies are a site of ebolavirus replication.

Authors:  Thomas Hoenen; Reed S Shabman; Allison Groseth; Astrid Herwig; Michaela Weber; Gordian Schudt; Olga Dolnik; Christopher F Basler; Stephan Becker; Heinz Feldmann
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

6.  DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function.

Authors:  Reed S Shabman; Daisy W Leung; Joshua Johnson; Nicole Glennon; Erol E Gulcicek; Kathryn L Stone; Lawrence Leung; Lisa Hensley; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation.

Authors:  Benjamin Yen; Lubbertus C F Mulder; Osvaldo Martinez; Christopher F Basler
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

8.  The authors reply.

Authors:  Viranuj Sueblinvong; Daniel W Johnson; Gary L Weinstein; Michael J Connor; Ian Crozier; Allison M Liddell; Harold A Franch; Bruce R Wall; Andre C Kalil; Mark Feldman; Steven J Lisco; Jonathan E Sevransky
Journal:  Crit Care Med       Date:  2016-06       Impact factor: 7.598

9.  A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection.

Authors:  Mukta Dutta; Shelly J Robertson; Atsushi Okumura; Dana P Scott; Jean Chang; Jeffrey M Weiss; Gail L Sturdevant; Friederike Feldmann; Elaine Haddock; Abhilash I Chiramel; Sanket S Ponia; Jonathan D Dougherty; Michael G Katze; Angela L Rasmussen; Sonja M Best
Journal:  Cell Rep       Date:  2017-01-17       Impact factor: 9.423

Review 10.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.